✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Neuland Laboratories Ltd.

NEULANDLAB

Market Cap
₹16,923 Cr.
P/E
65.06

Neuland Laboratories Ltd.

  • Neuland Laboratories
  • Gufic Biosciences
  • Alivus Life Sciences
  • TJI Pharma - Small Cap
FAQs on Neuland Laboratories Ltd. Shareprice

Neuland Laboratories has given better returns compared to its competitors.
Neuland Laboratories has grown at ~108.34% over the last 2yrs while peers have grown at a median rate of 36.48%

Yes, Neuland Laboratories is expensive.
Latest PE of Neuland Laboratories is 65.06, while 3 year average PE is 33.34.
Also latest EV/EBITDA of Neuland Laboratories is 51.97 while 3yr average is 20.41.

View FAQ's On Business
Growth Table
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences
Balance Sheet
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences
Cash Flow
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences
Quarterly Results
  • Neuland Laboratories Ltd.
  • Gufic Biosciences
  • Alivus Life Sciences
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Neuland Laboratories Ltd. Financials

Balance sheet of Neuland Laboratories is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Neuland Laboratories is increasing.
Latest net debt of Neuland Laboratories is -₹122.81 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹151.04 Crs.

The profit is oscillating.
The profit of Neuland Laboratories is ₹260 Crs for TTM, ₹300 Crs for Mar 2024 and ₹164 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Neuland Laboratories latest dividend payout ratio is 5.99% and 3yr average dividend payout ratio is 7.96%

NA

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech